We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

178 hedge funds and large institutions have $2.69B invested in Agios Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

4% more funds holding

Funds holding: 171 → 178 (+7)

1.21% more ownership

Funds ownership: 95.18% → 96.38% (+1.2%)

13% less capital invested

Capital invested by funds: $3.07B → $2.69B (-$388M)

33% less call options, than puts

Call options by funds: $10.2M | Put options by funds: $15.1M

80% less funds holding in top 10

Funds holding in top 10: 5 → 1 (-4)

Holders
178
Holders Change
+7
Holders Change %
+4.09%
% of All Funds
4.04%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.02%
New
30
Increased
66
Reduced
58
Closed
22
Calls
$10.2M
Puts
$15.1M
Net Calls
-$4.96M
Net Calls Change
-$9.09M

Top Buyers

1
UBS AM
UBS AM
Illinois
+$19.7M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$14.7M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$14M
4
PI
Putnam Investments
Massachusetts
+$13.3M
5
First Trust Advisors
First Trust Advisors
Illinois
+$10.7M

Top Sellers

1
Capital International Investors
Capital International Investors
California
-$20.5M
2
CI
Capital International
California
-$13.2M
3
QIM
Quantitative Investment Management
Virginia
-$10.3M
4
Invesco
Invesco
Georgia
-$8.69M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$8.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
126
Virtus ETF Advisers
New York
$379K +$11.9K +189 +3%
VFA
127
Virtus Fund Advisers
Connecticut
$379K +$417K +6,624 New
NSAM
128
North Star Asset Management
Wisconsin
$320K +$352K +5,600 New
Canada Life
129
Canada Life
Manitoba, Canada
$316K – – –
HI
130
HBK Investments
Texas
$306K +$337K +5,355 New
XK
131
Xact Kapitalforvaltning
Sweden
$259K +$285K +4,523 New
TI
132
Trexquant Investment
Connecticut
$211K +$232K +3,690 New
QIM
133
Quantitative Investment Management
Virginia
$205K -$10.3M -163,000 -98%
Bank of Montreal
134
Bank of Montreal
Ontario, Canada
$203K +$95.6K +1,520 +75%
SG Americas Securities
135
SG Americas Securities
New York
$196K -$264K -4,193 -55%
CWG
136
C WorldWide Group
Denmark
$183K -$37.8K -600 -16%
MLICM
137
Metropolitan Life Insurance Company (MetLife)
New York
$169K -$2.01K -32 -1%
SEI Investments
138
SEI Investments
Pennsylvania
$164K +$175K +2,785 +3,315%
QI
139
QS Investors
New York
$160K – – –
SOADOR
140
State of Alaska Department of Revenue
Alaska
$160K +$176K +2,800 New
Zurich Cantonal Bank
141
Zurich Cantonal Bank
Switzerland
$149K +$47.9K +762 +41%
JP Morgan Chase
142
JP Morgan Chase
New York
$89K +$5.66K +90 +6%
Manulife (Manufacturers Life Insurance)
143
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$85K +$1.13K +18 +1%
EMG
144
ETF Managers Group
New Jersey
$63K +$9.44K +150 +17%
Pacer Advisors
145
Pacer Advisors
Pennsylvania
$61K +$67.6K +1,075 New
CG
146
Cutler Group
California
$57K -$383K -6,084 -86%
AIG
147
American International Group
New York
$56K +$61.3K +974 New
MFT
148
Moisand Fitzgerald Tamayo
Florida
$43K – – –
CA
149
Calton & Associates
Florida
$23K +$18.9K +300 New
GWM
150
Geneos Wealth Management
Colorado
$20K +$13.8K +220 +161%
4 5
6
7 8

AGIO Hedge Fund Activity: Q4 2017 in Review

178 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2017, worth a combined $2.69B — down 13% from $3.07B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AGIO positions and 22 closed out — a net gain of 8 holders — while 66 added to existing stakes and 58 trimmed.

The largest buyer was UBS AM, adding an estimated $19.7M. The largest seller was Capital International Investors, cutting an estimated $20.5M.

  • 178 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2017, up from 171 in Q3 2017.
  • Funds reported $2.69B of Agios Pharmaceuticals stock for Q4 2017, down 13% quarter-over-quarter.
  • 30 funds opened new Agios Pharmaceuticals positions in Q4 2017 and 22 closed out, a net change of +8 holders.
  • The largest Agios Pharmaceuticals buyer in Q4 2017 was UBS AM, an estimated $19.7M added.
  • The largest Agios Pharmaceuticals seller in Q4 2017 was Capital International Investors, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2017.